Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Glioblastoma
Boron neutron capture therapy has been tested as an alternative treatment for glioblastoma multiforme but is not in common use.